TY  - JOUR
A1  - Rauch, Bernhard
A1  - Salzwedel, Annett
A1  - Bjarnason-Wehrens, Birna
A1  - Albus, Christian
A1  - Meng, Karin
A1  - Schmid, Jean-Paul
A1  - Benzer, Werner
A1  - Hackbusch, Matthes
A1  - Jensen, Katrin
A1  - Schwaab, Bernhard
A1  - Altenberger, Johann
A1  - Benjamin, Nicola
A1  - Bestehorn, Kurt
A1  - Bongarth, Christa
A1  - Dörr, Gesine
A1  - Eichler, Sarah
A1  - Einwang, Hans-Peter
A1  - Falk, Johannes
A1  - Glatz, Johannes
A1  - Gielen, Stephan
A1  - Grilli, Maurizio
A1  - Grünig, Ekkehard
A1  - Guha, Manju
A1  - Hermann, Matthias
A1  - Hoberg, Eike
A1  - Höfer, Stefan
A1  - Kaemmerer, Harald
A1  - Ladwig, Karl-Heinz
A1  - Mayer-Berger, Wolfgang
A1  - Metzendorf, Maria-Inti
A1  - Nebel, Roland
A1  - Neidenbach, Rhoia Clara
A1  - Niebauer, Josef
A1  - Nixdorff, Uwe
A1  - Oberhoffer, Renate
A1  - Reibis, Rona
A1  - Reiss, Nils
A1  - Saure, Daniel
A1  - Schlitt, Axel
A1  - Völler, Heinz
A1  - Känel, Roland von
A1  - Weinbrenner, Susanne
A1  - Westphal, Ronja
T1  - Cardiac rehabilitation in German speaking countries of Europe — evidence-based guidelines from Germany, Austria and Switzerland LLKardReha-DACH — Part 1
JF  - Journal of Clinical Medicine
N2  - Background: Although cardiovascular rehabilitation (CR) is well accepted in general, CR-attendance and delivery still considerably vary between the European countries. Moreover, clinical and prognostic effects of CR are not well established for a variety of cardiovascular diseases. Methods: The guidelines address all aspects of CR including indications, contents and delivery. By processing the guidelines, every step was externally supervised and moderated by independent members of the “Association of the Scientific Medical Societies in Germany” (AWMF). Four meta-analyses were performed to evaluate the prognostic effect of CR after acute coronary syndrome (ACS), after coronary bypass grafting (CABG), in patients with severe chronic systolic heart failure (HFrEF), and to define the effect of psychological interventions during CR. All other indications for CR-delivery were based on a predefined semi-structured literature search and recommendations were established by a formal consenting process including all medical societies involved in guideline generation. Results: Multidisciplinary CR is associated with a significant reduction in all-cause mortality in patients after ACS and after CABG, whereas HFrEF-patients (left ventricular ejection fraction <40%) especially benefit in terms of exercise capacity and health-related quality of life. Patients with other cardiovascular diseases also benefit from CR-participation, but the scientific evidence is less clear. There is increasing evidence that the beneficial effect of CR strongly depends on “treatment intensity” including medical supervision, treatment of cardiovascular risk factors, information and education, and a minimum of individually adapted exercise volume. Additional psychologic interventions should be performed on the basis of individual needs. Conclusions: These guidelines reinforce the substantial benefit of CR in specific clinical indications, but also describe remaining deficits in CR-delivery in clinical practice as well as in CR-science with respect to methodology and presentation.
KW  - cardiac rehabilitation standards
KW  - scientific guidelines
KW  - secondary prevention
KW  - coronary artery disease
KW  - chronic heart failure
KW  - heart valve repair
KW  - ICD-CRT
KW  - ventricular assist device
KW  - heart transplantation
KW  - peripheral artery disease
KW  - pulmonary hypertension
KW  - myocarditis
KW  - adults with congenital heart disease
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239709
SN  - 2077-0383
VL  - 10
IS  - 10
ER  - 
TY  - JOUR
A1  - Bannasch, Johannes H.
A1  - Berger, Benjamin
A1  - Schwartkopp, Claus-Peter
A1  - Berning, Marco
A1  - Goetze, Oliver
A1  - Panning, Marcus
A1  - Fritz-Weltin, Miriam
A1  - Trendelenburg, George
A1  - Gelderblom, Mathias
A1  - Lütgehetmann, Marc
A1  - Stute, Fridrike
A1  - Horvatits, Thomas
A1  - Dirks, Meike
A1  - Antoni, Christoph
A1  - Behrendt, Patrick
A1  - Pischke, Sven
T1  - HEV-associated neuralgic amyotrophy: a multicentric case series
JF  - Pathogens
N2  - Background: Neuralgic amyotrophy (NA) has been described as a possible extrahepatic manifestation of hepatitis E virus (HEV) infection. Usually, HEV-associated NA occurs bilaterally. The clinical characteristics determining the course of HEV-associated NA have still not been defined. Methods: In this retrospective multicentric case series, 16 patients with HEV-associated NA were studied and compared to 176 HEV patients without NA in terms of their age, sex, and ALT levels. Results: Neither gender distribution (75% vs. 67% male) nor age (47 vs. 48 years median) differed significantly between the NA patients and controls. Eight NA patients (50%) presented with bilateral involvement — seven of these had right-side dominance and one had left-side dominance. Thirteen cases (81%) were hospitalized. Eight of these patients stayed in hospital for five to seven days, and five patients stayed for up to two weeks. The time from the onset of NA to the HEV diagnosis, as well as the diagnostic and therapeutic proceedings, showed a large variability. In total, 13 (81%) patients received treatment: 1/13 (8%) received intravenous immunoglobulins, 8/13 (62%) received glucocorticoids, 3/13 (23%) received ribavirin, and 6/13 (46%) received pregabalin/gabapentin. Patients with ages above the median (47 years) were more likely to be treated (p = 0.001). Conclusion: HEV-associated NA causes a relevant morbidity. In our case series neither the type of treatment nor the time of initiation of therapy had a significant effect on the duration of hospitalization or the course of the disease. The clinical presentation, the common diagnostic and therapeutic procedures, and the patients' characteristics showed large variability, demonstrating the necessity of standardized protocols for this rare but relevant disease.
KW  - Hepatitis E
KW  - HEV
KW  - neuralgic amyotrophy
KW  - NA
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239691
SN  - 2076-0817
VL  - 10
IS  - 6
ER  -